DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation2 articles · 1 high · 1 moderate

21 CFR 211.165

Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.165: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under 21 CFR 211.165?
2 DSRV articles cite 21 CFR 211.165. Enforcement cases behind them: FDA Warning Letter CMS Case 723059 to Sato Pharmaceutical Co., Ltd., May 18, 2026; FDA draft guidance on Real-Time Release Testing (pharmaceutical modernization initiative); ICH Q8 / Q10. Inspection exposure across them: 1 high, 1 moderate.
What does DSRV recommend for 21 CFR 211.165?
From the newest article (Media-Fill Failure Is Not the Root Cause. It Is the Alarm Bell.): A media-fill failure is the alarm bell, not the root cause: after repeated failures FDA stops evaluating individual events and starts evaluating whether the quality unit ever accurately diagnosed the design failure driving them. DSRV's matching service is the Release Testing / RTRT Readiness, delivered through controlled intake at /submit. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 5 min readHigh exposurecited as a tag

    Media-Fill Failure Is Not the Root Cause. It Is the Alarm Bell.

    FDA’s May 18, 2026 warning letter to Sato Pharmaceutical describes six consecutive media-fill failures as a quality-system credibility collapse. The inspection-readiness lessons span ISO 5/RABS design, smoke studies, contamination prevention, and systemic CAPA, and they generalize far beyond Sato.

    Case
    FDA Warning Letter CMS Case 723059 to Sato Pharmaceutical Co., Ltd., May 18, 2026.
    DSRV take
    A media-fill failure is the alarm bell, not the root cause: after repeated failures FDA stops evaluating individual events and starts evaluating whether the quality unit ever accurately diagnosed the design failure driving them.
  2. 9 min readModerate exposure

    FDA's Evolving Stance on Real-Time Release Testing (RTRT)

    The FDA has issued new draft guidance on RTRT as part of its modernisation initiative. We examine the regulatory pathway, technical requirements, and what this means for PAT-enabled manufacturing lines.

    Case
    FDA draft guidance on Real-Time Release Testing (pharmaceutical modernization initiative); ICH Q8 / Q10.
    DSRV take
    RTRT only reduces burden when the underlying control strategy and model maintenance are documented well enough to defend a release without end-product testing.
Address this risk

Release Testing / RTRT Readiness

Bring the document that has to hold up under 21 CFR 211.165. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR 211.165

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.